Viva Biotech Holdings (01873) released its monthly return for February 2026, indicating that the authorized share capital remained at 4.00 billion ordinary shares with a par value of USD 0.000025 each, translating into total authorized share capital of USD 100,000. The number of issued shares stayed at 2.13 billion, with no changes during the month. The public float requirement remains at 25%, and there were no new share issuances, cancellations, or treasury share movements.

Pre-IPO share incentives stood at 2.22 million outstanding options, while post-IPO share options were 18.02 million. No additional shares were issued or canceled under these plans. The post-IPO plan allows for a maximum of 120.03 million shares to be issued or transferred. No funds were raised from share-option exercises in the reporting period.